ASX code: NRT
Listing Date: Thu, 1 Sep 1994
Website: http://www.novogen.com
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
Pharmaceutical research and development and manufacturing and marketing of health supplements.
Address:
140 Wicks Road
NORTH RYDE
NSW 2113
Phone: (02) 9878 0088
Fax: (02) 9878 0055
Executives & Directors
Mr Philip A Johnston, Chairman, Non Exec. Director
Mr Christopher Naughton, Executive Director, Managing Director, CEO
Prof. Alan James Husband, Executive Director
Mr Peter B Simpson, Non Exec. Director
Prof. Paul J Nestel, AO, Non Exec. Director
Mr Geoffrey M Leppinus, Non Exec. Director
Mr David R Seaton, CFO
Mr Ronald L Erratt, Company Secretary
Please contact the ASX to change these details
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
View this company's details on the Australian Securities Exchange website
NOVOGEN LIMITED (NRT) Events
Australia/NSW
NOVOGEN LIMITED (NRT)
| Marshall Edwards granted IND for triphendiol | Thu, 8 Jan 2009 |
| NV-128 potential activity against cancer stem cells | Tue, 2 Dec 2008 |
| IND filed for triphendiol | Tue, 2 Dec 2008 |
| Appendix 3Y | Tue, 2 Dec 2008 |
| IDMC recommends Marshall Edwards`s OVATURE Trial Continues | Thu, 13 Nov 2008 |
| Appendix 3B | Wed, 5 Nov 2008 |
| Results of Meeting | Mon, 3 Nov 2008 |
| Chairmans Report AGM 2008 | Fri, 31 Oct 2008 |
| Phenoxodiol and NV-128 show potent synergiatic effect | Wed, 29 Oct 2008 |
| Glycotex reports first patient in new study | Wed, 22 Oct 2008 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.
